Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2013-05, Vol.19 (10), p.2607-2612
Main Authors: KORN, Ronald L, CROWLEY, John J
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Disease Progression
Disease-Free Survival
Endpoint Determination - methods
Humans
Medical sciences
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - pathology
Neoplasms - therapy
Outcome Assessment (Health Care) - methods
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease progression is recorded. In this overview, we review the circumstances that can devalue the use of PFS as a primary endpoint and attempt to provide a pathway for a future desired state when PFS will become not just a secondary alternative to overall survival but rather an endpoint of choice.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-12-2934